Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety of opinions spanning from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.0, a high estimate of $57.00, and a low estimate of $45.00. Highlighting a 7.55% decrease, the current average has fallen from the previous average price target of $53.00.

Decoding Analyst Ratings: A Detailed Look

An in-depth analysis...